Anxiety disorders Stress-related disorders
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Age between 18 and 40 Right handed BMI between 18.5 and 30 Normal or corrected to normal vision Speaking and understanding of the English language
Exclusion criteria
Exclusion criteria: Incompatibility with the MRI scanner History of brain surgery Possible pregnancy Breastfeeding Color blindness Any relevant current or past psychiatric or psychotic disorder, including suicidality First degree family member with schizophrenia, bipolar disorder, or major depressive disorder Neurological disorder Endocrine disorder Endocrine treatment Glaucoma or increased risk for glaucoma Melanoma or undiagnosed skin lesion Any other clinically significant hepatic, metabolic, obstructive respiratory, renal, cerebrovascular, cardiovascular, oncological, ocular or pulmonary disease/disorders Raynaud*s syndrome Hypersensitivity to Haloperidol or Propranolol Hypertension (i.e. diastolic blood pressure >95 mmHg at rest, or systolic blood pressure >180 mmHg at rest) Hypotension (i.e. diastolic blood pressure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters are the comparison of oddball performance and performance in the cue-guided versus memory-guided attention task, between the stress and placebo group, the stress and haloperidol group, and the stress and propranolol group. | — |
Secondary
| Measure | Time frame |
|---|---|
| In this study, three secondary outcome parameters are measured. First, the difference in vigilance and striatal-dependent cognition between the group receiving Propranolol and the group receiving Haloperidol is investigated. Second, the difference in neural activity between the different groups is assessed during the oddball and visual search task. Third, the difference in behavioral measures and neural activity in the different groups is measured during a motivation task, a working memory task, and an emotion task. | — |
Countries
Netherlands